share_log

This Insider Has Just Sold Shares In Ironwood Pharmaceuticals

This Insider Has Just Sold Shares In Ironwood Pharmaceuticals

這位內部人士剛剛出售了艾恩伍德製藥的股票
Simply Wall St ·  05/23 18:31

Anyone interested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) should probably be aware that the CEO & Director, Thomas McCourt, recently divested US$436k worth of shares in the company, at an average price of US$6.45 each. The eyebrow raising move amounted to a reduction of 12% in their holding.

任何對艾恩伍德製藥公司(納斯達克股票代碼:IRWD)感興趣的人都應該知道,首席執行官兼董事托馬斯·麥考特最近以每股6.45美元的平均價格剝離了該公司價值43.6萬美元的股份。此次舉措使他們的持股量減少了12%。

The Last 12 Months Of Insider Transactions At Ironwood Pharmaceuticals

Ironwood Pharmicals最近12個月的內幕交易

Notably, that recent sale by CEO & Director Thomas McCourt was not the only time they sold Ironwood Pharmaceuticals shares this year. They previously made an even bigger sale of -US$2.7m worth of shares at a price of US$15.24 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$6.49. So it is hard to draw any strong conclusion from it.

值得注意的是,首席執行官兼董事托馬斯·麥考特最近的出售並不是他們今年唯一一次出售艾恩伍德製藥的股票。他們此前以每股15.24美元的價格進一步出售了價值-270萬美元的股票。雖然我們通常不喜歡看到內幕銷售,但更令人擔憂的是是否以較低的價格進行銷售。令人欣慰的是,此次出售的價格遠高於當前的股價,即6.49美元。因此,很難從中得出任何強有力的結論。

In the last twelve months insiders purchased 53.68k shares for US$461k. But they sold 417.10k shares for US$5.2m. All up, insiders sold more shares in Ironwood Pharmaceuticals than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

在過去的十二個月中,內部人士以46.1萬美元的價格購買了53.68萬股股票。但他們以520萬美元的價格出售了41.71萬股股票。總而言之,去年內部人士出售的Ironwood Pharmicals股票比他們買入的還要多。你可以在下面看到過去 12 個月內幕交易(公司和個人)的直觀描述。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NasdaqGS:IRWD Insider Trading Volume May 23rd 2024
納斯達克GS:IRWD 內幕交易量 2024 年 5 月 23 日

I will like Ironwood Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡艾恩伍德製藥公司。在我們等待的同時,請查看這份被低估的小盤股的免費清單,這些股票最近有大量的內幕買盤。

Insider Ownership Of Ironwood Pharmaceuticals

艾恩伍德製藥的內部所有權

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Ironwood Pharmaceuticals insiders own about US$16m worth of shares. That equates to 1.6% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。較高的內部所有權通常會使公司領導層更加關注股東的利益。艾恩伍德製藥內部人士擁有價值約1600萬美元的股票。這相當於該公司的1.6%。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。

So What Do The Ironwood Pharmaceuticals Insider Transactions Indicate?

那麼,艾恩伍德製藥的內幕交易表明了什麼?

The insider sales have outweighed the insider buying, at Ironwood Pharmaceuticals, in the last three months. Despite some insider buying, the longer term picture doesn't make us feel much more positive. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 3 warning signs for Ironwood Pharmaceuticals (of which 1 is potentially serious!) you should know about.

在過去的三個月中,Ironwood Pharmicals的內幕銷售超過了內幕收購。儘管有一些內幕買盤,但長期前景並不能使我們感到更加樂觀。儘管內部人士確實擁有股票,但他們並不擁有大量股票,他們一直在拋售。購買前我們會謹慎行事!因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解該公司面臨的風險。每家公司都有風險,我們已經發現了Ironwood Pharmicals的3個警告信號(其中1個可能很嚴重!)你應該知道。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論